Skip to main content

Advertisement

Table 1 Demographic and clinical characteristics of participants with severe or mild/moderate asthma and control subjects

From: PI3K inhibitor treatment ameliorates the glucocorticoid insensitivity of PBMCs in severe asthma

 Mild/moderate asthma
(n = 12)
Severe asthma
(n = 10)
Healthy control
(n = 12)
Sex (male vs. female)5 vs. 74 vs. 66 vs. 6
Age (years)45.0 ± 13.951.8 ± 12.048.2 ± 12.5
History (years)15.3 ± 10.911.9 ± 12.4ND
Allergic rhinitis (n, %)8 (66.7%)6 (60.0%)0 (0%)
FEV1% pre (mean ± SD)75.2 ± 12.763.2 ± 11.3*101 ± 15.5
FEV1/FVC (mean ± SD)83.7 ± 16.873.5 ± 18.5*97.9 ± 17.2
Bronchodilator responsiveness positive (n, %)12 (%)10 (%)ND
FeNO (ppb) (mean ± SD)38.9 ± 24.975.6 ± 21.5*19.2 ± 5.7
Eosinophils (× 109/l) (mean ± SD)0.27 ± 0.250.35 ± 0.18ND
IgE (IU/ml) (mean ± SD)263.9 ± 400.6303.7 ± 261.2ND
ACQ (mean ± SD)5.7 ± 1.511.9 ± 2.9*ND
ACT (mean ± SD)22.9 ± 6.816.8 ± 5.1*ND
≥ 1 Acute exacerbation during the previous year (n, %)2 (16.7%)6 (60.0%)ND
  1. FEV1% pre forced expiratory volume in 1 s, FVC forced volume capacity, FeNO fraction of exhaled nitric oxide, ACQ Asthma Control Questionnaire, ACT asthma control test, ND not detected
  2. *p < 0.05 (compared to mild/moderate asthma)